All rights reserved. Printed in the United States of America. No part of this publication may be reproduced, distributed, or transmitted, in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher. The content and reliability of the articles are the responsibility of the authors. When using and borrowing materials reference to the publication is required. Collection of scientific articles published is the scientific and practical publication, which contains scientific articles of students, graduate students, Candidates and Doctors of Sciences, research workers and practitioners from Europe and Ukraine. The articles contain the study, reflecting the processes and changes in the structure of modern science.
Summary. Aim: To assess the expression of Ki-67 protein and CD34 antigen on peripheral blood (PB) and bone marrow (BM) cells in chronic myelogenous leukemia (CML) patients with different response to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) therapy. Patients and Methods: BM aspirate and PB samples from 41 CML patients treated with IM and NI were studied by cytogenetic, molecular genetic, and flow cytometry methods. According to the response to TKIs, the patients were distributed into the optimal response, warning, and treatment failure groups. Results: The patients with optimal response to TKI therapy showed the lowest levels of Ki-67 expression in PB and BM compared with the patients from warning and falure treatment groups, however, Ki-67 expression was close to the reference values in PB (0.7 ± 0.3)%, only in NI-treated patients, The highest expression of Ki-67 in PB was observed in patients from treatment failure groups. In PB of patients who received NI and did not achieve optimal response, CD34+ cell count increased by almost 4 times compared with that in the optimal response group. The results indicated that CD34+ cell pool expanded in patients with poor response to both IM and NI. In patients with optimal response to NI therapy, CD34+ cell counts in PB were within the reference range and did not exceed 0.5%. Similar results were observed for Ki-67 and CD34+ in BM hematopoietic cells. Conclusions: Ki-67 expression and CD34+ cell count in PB and BM of CML patients increased with the acquisition of clonal resistance to IM and NI. NI provides a deeper molecular response compared with IM.
Background:The main feature of CML is the formation of the BCR-ABL gene, the product of which has a pronounced tyrosine kinase activity, which is due to the suppressing effect of the protein regulators of proliferation and apoptosis. The result is an increase of the proliferation of tumor cells, the marker of which is the Ki-67 protein. It is also known that the cause of the leukemic clone cell resistance to TKI treatment is the mutations in the genome of the early CD34+-progenitor cells that acquire the ability to proliferate. This leads to the expansion of CD34+cells Aims: Evaluate the expression of Ki-67 protein and antigen CD34 by haematopoietic cells of PB and BM in CML patients with different response to imatinib (IM) and nilotinib (NI) therapy. Methods: We included 67 patients with CP-CML treated with IM and 22 patients treated with NI in study. The studies were conducted on a FACscan flow laser cytometer. The number of cells expressing Ki-67 and CD34-cells was determined. Results: Data analysis showed that in CML patients with the best response to TKI therapy the lowest values of Ki-67 protein expression were observed in PB and BM in comparison to patients of all other groups, but only in patients treated with NI this indicator was close to the reference values in PB (0.7 ± 0.3)%, whereas in patients taking IM it was equal to (2.86 ± 1.3)%, on the basis of which it can be assumed that NI is more potently acts on the stem leukemic cells. A comparison between groups with different responses to TKI treatment showed that the highest expression of Ki-67 in PB was observed in patients with unsatisfactory response. Thus, the Ki-67 score was 7 times higher in the warning group and more than 6 times higher in the treatment failure group compared with the optimal response (p < 0.05) in both groups with IM and NI. The difference in expression of KI-67 in patient groups who received IM and NI and did not achieve a good response is not indicated. Similar results were obtained in the study of BM. Immunophenotypic quantitative monitoring of CD34+-cells in PB and BM in CML patients with a different response to IM and NI therapy was performed. Data analysis showed that in the PB of patients with an unsatisfactory response, the number of CD34+-hemopoietic precursor cells exceeded the same value in patients with the optimal response (p < 0.05). Thus, the expression of CD34 in warning group patients to IM therapy was 2.4 times higher than the optimal response, and in the group of failure therapy -4.3 times. Concerning the expression of CD34 in the PB of patients treated with NI and did not achieve optimal response, there was an increase of CD34+ cells in the PB by almost 4 times compared with the optimal response group. The results suggest that the pool of CD34+ cells is expanded in the PB of patients with an unsatisfactory response to both IM and NI. It should be noted that in patients with an optimal response to NI, expression of CD34+ cells in the PB was within the reference range and did not exceed 0.5%. Instead, in pati...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.